read.qxmd.com Open in urlscan Pro
2606:4700:4400::ac40:9633  Public Scan

Form analysis
0 forms found in the DOM

Text Content

PapersTopics

0
SupportLoginSign Up

Featured FeedJournalsCollectionsKeywordsSaved Papers

JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers


PROLACTIN IN POLYCYSTIC OVARY SYNDROME: METABOLIC EFFECTS AND THERAPEUTIC
PROSPECTS.

Lara Mastnak, Rok Herman, Simona Ferjan, Andrej Janež, Mojca Jensterle
Life 2023 October 27
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine and metabolic
disorder in premenopausal women, characterized by hyperandrogenism, ovulatory
dysfunction, and polycystic ovaries. Patients frequently present comorbidities,
including obesity, insulin resistance, and impaired glucose and lipid
metabolism. The diverse clinical presentation may mimic various endocrine
disorders, making the diagnosis challenging in some clinical circumstances.
Prolactin (PRL) is a recommended biomarker in the initial diagnostic workup to
rule out hyperprolactinemia (HPRL). The traditional role of PRL is linked to
lactation and the reproductive system. Recent research highlights PRL's emerging
role in metabolic homeostasis. PRL influences metabolism directly by interacting
with the pancreas, liver, hypothalamus, and adipose tissue. Its influence on an
individual's metabolism is intricately tied to its serum concentration. While
deficient and very high levels of PRL can negatively affect metabolism,
intermediate-normal to moderately high levels may promote metabolic health. In
women with PCOS, PRL levels may be altered. Research results on different
aspects of the relationship between PCOS and the impact of various levels of PRL
on metabolic homeostasis are limited and inconsistent. In this narrative
literature review, we comprehensively examined data on serum PRL levels in PCOS
patients. We investigated the correlation between a favorable metabolic profile
and serum PRL levels in this population. Furthermore, we explored the concept of
beneficial PRL effects on metabolism and discussed the potential therapeutic
application of dopamine agonists in PCOS treatment. Lastly, we emphasized
several promising avenues for future research in this field.



FULL TEXT LINKS

We have located open access text paper links.
Full Text PDFFull Text Web
Show additional links to paperHide additional links to paper
PubMedMultidisciplinary Digital Publishing Institute #1Multidisciplinary Digital
Publishing Institute #2PubMed Central #1Multidisciplinary Digital Publishing
Institute #3PubMed Central #2


Add to Saved Papers

Get 1-tap access

Share


CONVERSATION

Follow this conversation to be notified when new comments are posted follow
following
Log in | Sign up


All Comments
NEWEST

0


ALL COMMENTS

Start the conversation



Powered by



FOR THE BEST EXPERIENCE, USE THE READ MOBILE APP

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of
Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With
Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose
cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of
cardiovascular events primarily by reducingSeptember 1, 2017: JAMA
CardiologyAssociations of albuminuria in patients with chronic heart failure:
findings in the ALiskiren Observation of heart Failure Treatment
study.CONCLUSIONS: Increased UACR is common in patients with heart failure,
including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal
of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical
Stability Among Patients With Advanced Heart Failure and Reduced Ejection
Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Get app
Do Not Sell My Personal InformationManage Cookie Preferences

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By
using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Get app






WE CARE ABOUT YOUR PRIVACY

We and our 778 partners store and/or access information on a device, such as
unique IDs in cookies to process personal data. You may accept or manage your
choices by clicking below, including your right to object where legitimate
interest is used, or at any time in the privacy policy page. These choices will
be signaled to our partners and will not affect browsing data.


WE AND OUR PARTNERS PROCESS DATA TO PROVIDE:

Use precise geolocation data. Actively scan device characteristics for
identification. Store and/or access information on a device. Personalised
advertising and content, advertising and content measurement, audience research
and services development. List of Partners (vendors)

I Accept Show Purposes